Analyst Josh Jennings of TD Cowen maintained a Buy rating on Boston Scientific, retaining the price target of $115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong financial performance and positive outlook. The company exceeded market expectations in the third quarter, achieving sales and earnings per share (EPS) that surpassed analyst estimates. This robust performance was driven by impressive organic sales growth of 15.3%, outpacing the company’s own guidance.
Furthermore, Boston Scientific has raised its guidance for the third time this year, now projecting higher organic sales growth and EPS for 2025. The company also anticipates improvements in its adjusted gross and operating margins. These factors, combined with strong performances in key segments such as Electrophysiology and Watchman, underpin Jennings’s confidence in the stock’s potential, leading to the Buy rating.
In another report released today, Evercore ISI also maintained a Buy rating on the stock with a $113.00 price target.
Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.